TYROSINE AND C-KINASE ACTIVITY AND PI TURNOVER IN T-CELL
TYROSINE AND C-KINASE ACTIVITY AND PI TURNOVER IN T-CELL
批准号:
3299792
负责人:
Andre Elias Nel
金额:
$9.56万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-09-01 至 1991-08-31
关键词:
T lymphocyte adenylate cyclase calcium complementary DNA flow cytometry gel electrophoresis guanine nucleotide binding protein human tissue immunoprecipitation inositol phosphates interleukin 2 laboratory rabbit lectin leukocyte activation /transformation membrane lipids monoclonal antibody phosphatidylinositols phospholipase C phosphorylation protein kinase C protein tyrosine kinase receptor
中文摘要
T淋巴细胞可通过CD2和CD3受体被激活
通过使用特定的M.Ab和有丝分裂凝集素。许多人
需要第二个使者为后续的活动搭建舞台
通过分泌IL-2和表达IL-2实现自分泌增殖
它的受体。长期目标是理解
磷脂代谢、C-激酶活性与细胞的重要性
CA2沿着这些激活途径的观点来定义
疾病反应调整的目标区域。一个
对这些机制的理解也可能解释
某些免疫缺陷的病理生理学基础。
因此,特定的目的是使用结核分枝杆菌抗体和有丝分裂凝集素
明确C-激酶和CA2i.t.o的细胞生物学作用.I1-2
受体表达,底物磷酸化,受体
C-fos、c-myc、IL-2、
γ-干扰素和IL-2受体。这些研究还将着眼于
C-激酶激活之前的一些过程,
即PI周转、IP3、释放、Ca~2通量和受体
聚合。这可能揭示出效力的不同。
例如在凝集素之间生成第二信使
和抗T_3 M抗体。化学调节剂/药物对药物的影响
这些过程也将被审查。信号转导作用
将研究与受体相关的G结合蛋白
它们刺激腺苷环化酶的潜力
磷脂酶C活性。体内试验的重要性
细胞的自磷酸化、易位和蛋白水解性激活
将解决C-激酶的问题。最后,重要的相互作用
带有酪氨酸激酶的C-激酶,pp56Tck,将用
了解膜之间可能的联系的观点
磷脂代谢和有丝分裂事件。
为了进行这些研究,采用了以下方法
已经发展起来:蛋白质磷酸化研究,
特定磷酸化底物的免疫沉淀,SDS-
PAGE和放射自显影,磷酸氨基酸分析,薄层层析
磷脂萃取物,离子交换层析测定
IP3释放和胞质斑点杂交分析。完好无损
细胞反应通过流式细胞术、~3H-TD摄取、
IL-2分泌和Quin-2荧光。
英文摘要
T-lymphocytes can be activated via the CD2 and CD3 receptors
through the use of specific M.Ab and mitogenic lectins. A host of
second messengers are required to set the stage for subsequent
autocrine proliferation through secretion of IL-2 and expression of
its receptor. The long term objective is an understanding of the
importance of phospholipid metabolism, C-kinase activity and cell
CA+2 along these activation pathways with the view to define
target areas for response modification in disease. An
understanding of these mechanisms may also explain the
pathophysiological basic of certain immuno-deficiencies.
The specific aims are therefore to use M.Ab and mitogenic lectins
to define the cell biological role of C-kinase and CA+2 i.t.o. I1-2
receptor expression, substrate phos-phorylation, receptor
modulation and expression of mRNA for c-fos, c-myc, IL-2,
gamma-IFN, and the IL-2 receptor. These studies will also look at
some of the processes which precedes the activation of C-kinase,
namely PI turnover, IP3, release, CA+2 flux and receptor
aggregation. This may reveal differences in the potency by which
second messengers are generated, for instance between lectins
and anti-T3 M.Ab. The influence of chemical modulators/drugs on
these processes will also be examined. The signal transducing role
of receptor related G-binding proteins will be investigated in
terms of their potential for stimulating both adenylate cyclase
and phospholipase C activities. The importance of in vivo
autophosphorylation, translocation and proteolytic activation of
C-kinase will be addressed. Finally, the important interaction of
C-kinase with the tyrosine kinase, pp56 Tck, will be studied with a
view to understanding the possible link between membrane
phospholipid metabolism and mitogenic events.
In order to perform these studies, the following methodology has
been developed: protein phosphorylation studies,
immunoprecipitation of specific phosphorylated substrates, SDS-
PAGE and autoradiography, phospho-amino acid analysis, TLC of
phospholipid extracts, ion exchange chromatography to measure
IP3 release and cytoplasmic dot-blot analysis for mRNA. Intact
cell responses are monitored by flow cytometry, 3H-Td uptake,
IL-2 secretion and Quin 2 fluorescence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10187533
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10058189
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10417161
-
项目类别:
-
资助金额:$52.93万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
-
批准号:10654816
-
项目类别:
-
资助金额:$51.28万
-
财政年份:2020
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9186735
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9341321
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
-
批准号:9769728
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2016
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8206804
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8464703
-
项目类别:
-
资助金额:$105.49万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8393965
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Administrative Core
-
批准号:8067636
-
项目类别:
-
资助金额:$6.89万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8147701
-
项目类别:
-
资助金额:$109.06万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Center for Nanobiology and Predictive Toxicology
-
批准号:8274480
-
项目类别:
-
资助金额:$107.03万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8795269
-
项目类别:
-
资助金额:$2.28万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605676
-
项目类别:
-
资助金额:$6.46万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Project 2: Relating ENM Physicochemical Properties to Mechanism-Based Pulmonary T
-
批准号:8067631
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8537555
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8410038
-
项目类别:
-
资助金额:$36.93万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:8605860
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
-
批准号:7795767
-
项目类别:
-
资助金额:$42.07万
-
财政年份:2010
-
负责人:Andre Elias Nel
-
依托单位:
海外基金